

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 1 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

以下測試之樣品係由申請廠商所提供及確認：

產品名稱： 舒沐康微細粒粉末+薑黃95%
申請廠商： 沅泰藥業有限公司
申請廠商地址： 臺中市西區民權路185號10樓之14
電話/聯絡人： 04-22297778/沅泰藥業有限公司
樣品包裝： 請參考報告末頁樣品照片
數量： 200g/瓶;共1瓶
樣品保存方式： 室溫
產品型號： ---
產品批號： 62505921
製造/國內負責廠商： 沅泰藥業有限公司
製造日期： 2025/05/10
有效期限： 2029/05/10
收樣日期： 2026年01月16日
測試日期： 2026年01月16日 ~ 2026年01月30日

測試結果： -請見下頁-

陳新智
SGS TAIWAN LTD
SGS
TAIWAN

陳新智 經理
台灣檢驗科技股份有限公司
報告簽署人

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 2 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

測試結果：

| 測試項目 | 測試方法 | 測試結果 | 定量/偵測極限 | 單位 |
|--------------------------|------------------------------------------------------------------------------------------------------------|------|---------|------------------------|
| 365項西藥定性分析 | --- | --- | --- | --- |
| 本樣品檢測共365項西藥定性分析(項目詳見附錄) | 本測試依實驗室內部方法(TESP-UB-0173, TESP-UB-0181, TESP-UB-0182), 以薄層層析法(TLC), 液相層析離子阱質譜儀(LC/MS/MS)或氣相層析質譜儀(GC/MS)檢測。 | N.D. | --- | ppm($\mu\text{g/g}$) |

備註：

1. 測試報告僅就委託者之委託事項提供測試結果，不對產品合法性做判斷。
2. 本測試報告之所有檢驗內容，均依委託事項執行檢驗，如有不實，願意承擔完全責任。
3. 本報告不得分離，分離使用無效。
4. 若該測試項目屬於定量分析則以「定量極限」表示；若該測試項目屬於定性分析則以「偵測極限」表示。
5. 低於定量極限/偵測極限之測定值以「N.D.」或「陰性」表示。微生物測試低於定量極限以「<定量極限值」表示。

- END -

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 3 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-------------------------------|--------------|------|----------------------------|-------------|------|
| 2,4-Dinitrophenol | 51-28-5 | 3600 | Benzathine-penicillin | 41372-02-5 | 3300 |
| 2-Diphenylmethylpyrrolidine | 22348-31-8 | 900 | Benzbromarone | 3562-84-3 | 900 |
| 7-keto-Dehydroepiandrosterone | 566-19-8 | 3000 | Benzhexol | 144-11-6 | 1800 |
| Acetaminophen | 103-90-2 | 300 | Benzocaine | 94-09-7 | 300 |
| Acetil acid | 147676-78-6 | 1500 | Benzylamine | 642-72-8 | 348 |
| Acetildenafil | 831217-01-7 | 600 | Betamethasone | 378-44-9 | 900 |
| Acetohexamide | 968-81-0 | 750 | Betamethasone 21 Acetate | 987-24-6 | 4500 |
| Acetophenetidin | 62-44-2 | 3600 | Betamethasone Benzoate | 22298-29-9 | 3225 |
| Acetylvardenafil | 1261351-28-3 | 600 | Betamethasone Dipropionate | 5593-20-4 | 1050 |
| Acrinol | 1837-57-6 | 2832 | Betamethasone Valerate | 2152-44-5 | 108 |
| Allopurinol | 315-30-0 | 600 | Bezafibrate | 41859-67-0 | 600 |
| Ambroxol | 18683-91-5 | 600 | Bisacodyl | 603-50-9 | 600 |
| Aminophylline | 317-34-0 | 4500 | Bisoprolol Fumarate | 104344-23-2 | 60 |
| Aminopyrine | 58-15-1 | 900 | Bromhexine | 3572-43-8 | 1200 |
| Aminotadalafil | 385769-84-6 | 900 | Bromopride | 4093-35-0 | 60 |
| Amitriptyline | 549-18-8 | 750 | Brompheniramine | 86-22-6 | 1800 |
| Amlodipine | 88150-42-9 | 300 | Bromvalerylurea | 496-67-3 | 1950 |
| Amoxicillin | 26787-78-0 | 4320 | Bucetin | 1083-57-4 | 600 |
| Amphetamine | 300-62-9 | 375 | Bufexamac | 2438-72-4 | 1650 |
| Ampicillin | 69-53-4 | 2700 | Buspirone | 36505-84-7 | 3600 |
| Apomorphine | 58-00-4 | 600 | Butropium | 107080-63-7 | 3000 |
| Aspirin | 50-78-2 | 600 | Caffeine | 58-08-2 | 600 |
| Astemizole | 68844-77-9 | 150 | Camyllofine | 54-30-8 | 3000 |
| Atenolol | 29122-68-7 | 300 | Carbamazepine | 298-46-4 | 3600 |
| Atorvastatin | 134523-00-5 | 420 | Carbetapentane | 77-23-6 | 150 |
| Atropine | 51-55-8 | 150 | Carbimazole | 22232-54-8 | 600 |
| Avanafil | 330784-47-9 | 600 | Carbinoxamine | 486-16-8 | 1650 |
| Baclofen | 1134-47-0 | 300 | Carbodenafil | 944241-52-5 | 1500 |
| Barbital | 57-44-3 | 750 | Carisoprodol | 78-44-4 | 375 |
| Benazepril | 86541-75-5 | 450 | Carvedilol | 72956-09-3 | 2400 |
| Benproperine | 2156-27-6 | 600 | Cefamandole nafate | 42540-40-9 | 150 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 4 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(µg/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|------------------------|-------------|------|-------------------------|-------------|------|
| Cefazolin | 25953-19-9 | 1050 | Cloperastine | 3703-76-2 | 1500 |
| Cefoperazone dihydrate | 113826-44-1 | 300 | Clotrimazole | 23593-75-1 | 3000 |
| Cefotaxime | 63527-52-6 | 150 | Cloxacillin Sodium | 7081-44-9 | 4770 |
| Ceftriaxone | 73384-59-5 | 4224 | Clozapine | 5786-21-0 | 600 |
| Celecoxib | 169590-42-5 | 900 | Cocaine | 50-36-2 | 750 |
| Cephalexin | 15686-71-2 | 75 | Colchicine | 64-86-8 | 750 |
| Cephradine | 38821-53-3 | 81 | Cortisone | 53-06-5 | 750 |
| Cetilistat | 282526-98-1 | 1500 | Cortisone acetate | 50-04-4 | 3600 |
| Cetirizine | 83881-51-0 | 159 | Cyproheptadine | 129-03-3 | 1500 |
| Chloramphenicol | 56-75-7 | 1200 | Desacetyl bisacodyl | 603-41-8 | 600 |
| Chlordiazepoxide | 58-25-3 | 300 | Desacetyl diltiazem | 42399-40-6 | 60 |
| Chlorhexidine | 55-56-1 | 2400 | Dexamethasone | 50-02-2 | 1200 |
| Chlormezanone | 80-77-3 | 60 | Dexamethasone phosphate | 312-93-6 | 900 |
| Chloropretadalafil | 171489-59-1 | 1500 | Dextromethorphan | 125-71-3 | 1500 |
| Chlorothiazide | 58-94-6 | 750 | Diazepam | 439-14-5 | 300 |
| Chlorpheniramine | 113-92-8 | 1200 | Dibucaine | 85-79-0 | 450 |
| Chlorpromazine | 50-53-3 | 300 | Diclofenac | 15307-86-5 | 600 |
| Chlorpropamide | 94-20-2 | 600 | Dicyclomine | 77-19-0 | 375 |
| Chlortetracycline | 57-62-5 | 600 | Diethylpropion | 39648-50-5 | 450 |
| Chlorzoxazone | 95-25-0 | 1050 | Diethylstilbestrol | 56-53-1 | 600 |
| Cimetidine | 51481-61-9 | 1500 | Difloxacin | 98106-17-3 | 3000 |
| Cinnarizine | 298-57-7 | 600 | Digitoxin | 71-63-6 | 450 |
| Ciprofloxacin(CFA) | 85721-33-1 | 240 | Dihydroergotamine | 511-12-6 | 150 |
| Clenbuterol | 21898-19-1 | 900 | Diltiazem | 42399-41-7 | 300 |
| Clindamycin HCl | 21462-39-5 | 456 | Dimenhydrinate | 523-87-5 | 150 |
| Clindamycin phosphate | 24729-96-2 | 150 | Dimethylsildenafil | 496835-35-9 | 3000 |
| Clobenzorex | 13364-32-4 | 375 | Dimetridazole | 551-92-8 | 150 |
| Clobetasol Propionate | 25122-46-7 | 2400 | Diphenhydramine | 58-73-1 | 375 |
| Clofibrate | 637-07-0 | 1500 | Diphenylhydantoin | 57-41-0 | 150 |
| Clonazepam | 1622-61-3 | 150 | Diprophylline | 479-18-5 | 900 |
| Clonidine | 4205-90-7 | 300 | Dipyridamole | 58-32-2 | 450 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 5 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm($\mu\text{g/g}$)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-------------------------------|--------------|------|---------------------------|-------------|-------|
| Dipyron | 68-89-3 | 600 | Fluocinonide | 356-12-7 | 3600 |
| Dithio-desmethyl-carbodenafil | 1333233-46-7 | 1500 | Fluoxetine | 54910-89-3 | 1200 |
| Doxazosin | 74191-85-8 | 2400 | Fluoxymesterone | 76-43-7 | 600 |
| Doxycycline | 564-25-0 | 576 | Flurbiprofen | 5104-49-4 | 150 |
| Doxylamine | 469-21-6 | 60 | Fluvastatin | 93957-54-1 | 1200 |
| Dyclonine Hydrochloride | 536-43-6 | 3600 | Furosemide | 54-31-9 | 600 |
| Econazole | 27220-47-9 | 150 | Gemfibrozil | 25812-30-0 | 4500 |
| Enrofloxacin | 93106-60-6 | 3090 | Gendenafil | 147676-66-2 | 3000 |
| Eprazinone | 10402-90-1 | 300 | Glibenclamide | 10238-21-8 | 4800 |
| Erythromycin | 114-07-8 | 240 | Glimepiride | 93479-97-1 | 2400 |
| Estazolam | 29975-16-4 | 60 | Glipizide | 29094-61-9 | 3000 |
| Estradiol | 50-28-2 | 1200 | Glycopyrronium | 740028-90-4 | 900 |
| Estradiol benzoate | 50-50-0 | 600 | Griseofulvin | 126-07-8 | 450 |
| Estriol | 50-27-1 | 60 | Guaifenesin | 93-14-1 | 2400 |
| Estrone | 53-16-7 | 30 | Haloperidol | 52-86-8 | 1620 |
| Ethinyl estradiol | 57-63-6 | 30 | Homatropine | 87-00-3 | 150 |
| Ethisterone | 434-03-7 | 600 | Homosildenafil | 642928-07-2 | 1350 |
| Ethoxybenzamide | 938-73-8 | 600 | Hydralazine | 86-54-4 | 450 |
| Ethylestrenol | 965-90-2 | 30 | Hydrochlorothiazide | 58-93-5 | 600 |
| Etodolac | 41340-25-4 | 600 | Hydrocortisone | 50-23-7 | 750 |
| Etofibrate | 31637-97-5 | 3000 | Hydroxyacetildenafil | 147676-56-0 | 600 |
| Famotidine | 76824-35-6 | 750 | Hydroxyhomosildenafil | 139755-85-4 | 1200 |
| Fenbufen | 36330-85-5 | 1875 | Hydroxythiohomosildenafil | 479073-82-0 | 1650 |
| Fenfluramine | 458-24-2 | 375 | Hydroxyvaridenafil | 224785-98-2 | 1500 |
| Fenofibrate | 49562-28-9 | 150 | Hydroxyzine | 2192-20-3 | 900 |
| Fenoterol | 13392-18-2 | 750 | Ibuprofen | 15687-27-1 | 1200 |
| Finasteride (Proscar) | 98319-26-7 | 3000 | Imidazosagatriazinone | 139756-21-1 | 1200 |
| Flavoxate | 15301-69-6 | 900 | Imipramine | 50-49-7 | 60 |
| Flibanserin | 167933-07-5 | 3600 | Indapamide | 26807-65-8 | 2400 |
| Fluconazole | 86386-73-4 | 480 | Indomethacin | 53-86-1 | 1200 |
| Flufenamic acid | 530-78-9 | 4050 | Isoniazid | 54-85-3 | 302.4 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 6 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|---------------------------|-------------|------|----------------------------------|-------------|------|
| Ketoconazole | 65277-42-1 | 300 | Metronidazole | 443-48-1 | 900 |
| Ketoprofen | 22071-15-4 | 450 | Mexiletine | 31828-71-4 | 1500 |
| Ketotifen fumarate | 34580-14-8 | 60 | Midazolam | 59467-70-8 | 60 |
| Lidocaine | 137-58-6 | 60 | Minocycline | 10118-90-8 | 750 |
| Lincomycin | 154-21-2 | 1710 | Minoxidil | 38304-91-5 | 600 |
| Liothyronine | 6893-02-3 | 3600 | Morphine | 57-27-2 | 150 |
| Lomefloxacin | 98079-51-7 | 1500 | Nalidixic acid | 389-08-2 | 300 |
| Lorazepam | 846-49-1 | 300 | Naloxone | 465-65-6 | 384 |
| Lorcaserin | 616202-92-7 | 900 | Naltrexone | 16590-41-3 | 2370 |
| Maprotiline | 10262-69-8 | 150 | Nandrolone | 434-22-0 | 750 |
| Mazindol | 22232-71-9 | 1950 | Naphazoline Hydrochloride | 835-31-4 | 300 |
| Meclizine | 569-65-3 | 60 | Naproxen | 22204-53-1 | 900 |
| Mefenamic acid | 61-68-7 | 900 | <i>N</i> -Desethylvardenafil | 448184-46-1 | 3000 |
| Melatonin | 73-31-4 | 1200 | <i>N</i> -Desethylacetildenafil | 147676-55-9 | 3000 |
| Meloxicam | 71125-38-7 | 4500 | <i>N</i> -Desmethylsibutramine | 168835-59-4 | 3000 |
| Meperidine | 57-42-1 | 150 | <i>N</i> -Desmethylsildenafil | 139755-82-1 | 3000 |
| Mephenesin | 59-47-2 | 150 | <i>N</i> -Didesmethylsibutramine | 84467-54-9 | 3000 |
| Mephentermine | 100-92-5 | 240 | Nefopam | 13669-70-0 | 300 |
| Meproamate | 57-53-4 | 375 | Nicametate | 3099-52-3 | 2550 |
| Metformin | 657-24-9 | 300 | Nicotine | 54-11-5 | 60 |
| Methamphetamine | 537-46-2 | 750 | Nifedipine | 21829-25-4 | 600 |
| Methandriol | 521-10-8 | 2400 | Nifuroxazide | 965-52-6 | 540 |
| Methandrostenolone | 72-63-9 | 600 | Nitrazepam | 146-22-5 | 600 |
| Methaqualone | 72-44-6 | 900 | Nitrofurantoin | 67-20-9 | 450 |
| Metharbital | 50-11-3 | 750 | Nitrofurazone | 59-87-0 | 4410 |
| Methimazole | 60-56-0 | 300 | Noracetildenafil | 949091-38-7 | 300 |
| Methyl DOPA-Sesquihydrate | 41372-08-1 | 1620 | Noraminyprine | 519-98-2 | 2400 |
| Methylprednisolone | 83-43-2 | 750 | Norethisterone | 68-22-4 | 600 |
| Methyltestosterone | 58-18-4 | 600 | Norfloxacin | 70458-96-7 | 300 |
| Metoclopramide | 364-62-5 | 750 | Norfludiazepam | 2886-65-9 | 150 |
| Metoprolol | 51384-51-1 | 150 | Norgestrel | 6533-00-2 | 600 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 7 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm($\mu\text{g/g}$)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-----------------------|-------------|------|----------------|-------------|------|
| Norneosildenafil | 371959-09-0 | 1000 | Piperidenafil | 224788-34-5 | 1500 |
| Nortadalafil | 171596-36-4 | 1500 | Pirenzepine | 28797-61-7 | 1350 |
| Noscapine | 128-62-1 | 300 | Piroxicam | 36322-90-4 | 600 |
| Nylidrin | 849-55-8 | 4500 | Prazosin | 19216-56-9 | 300 |
| Ofloxacin | 82419-36-1 | 1920 | Prednisolone | 50-24-8 | 1200 |
| Omeprazole | 73590-58-6 | 1200 | Prednisone | 53-03-2 | 750 |
| Orlistat | 96829-58-2 | 375 | Prilocaine | 721-50-6 | 750 |
| Orphenadrine | 83-98-7 | 300 | Primidone | 125-33-7 | 30 |
| Oxeladin | 468-61-1 | 120 | Probenecid | 57-66-9 | 900 |
| Oxethazaine | 126-27-2 | 150 | Procaine | 59-46-1 | 300 |
| Oxybutynin | 5633-20-5 | 4635 | Progesterone | 57-83-0 | 600 |
| Oxymetholone | 434-07-1 | 1050 | Promethazine | 60-87-7 | 300 |
| Oxyphenbutazone | 129-20-4 | 450 | Propafenone | 54063-53-5 | 2400 |
| Oxyphencylimine | 125-53-1 | 75 | Propantheline | 298-50-0 | 3000 |
| Oxytetracycline (OTC) | 79-57-2 | 960 | Propranolol | 525-66-6 | 1350 |
| Papaverine | 58-74-2 | 1560 | Propyphenazone | 479-92-5 | 3000 |
| Pentazocine | 359-83-1 | 30 | Quetiapine | 111974-69-7 | 2400 |
| Pentobarbital | 76-74-4 | 150 | Quinine | 130-95-0 | 300 |
| Pentoxifylline | 6493-05-6 | 2400 | Ranitidine | 66357-59-3 | 600 |
| Phenacetin | 62-44-2 | 3600 | Reserpine | 50-55-5 | 1200 |
| Phenazopyridine | 94-78-0 | 750 | Rifampin | 13292-46-1 | 120 |
| Phenformin | 114-86-3 | 900 | Rimonabant | 168273-06-1 | 3000 |
| Phenobarbital | 50-06-6 | 900 | Rosiglitazone | 122320-73-4 | 3000 |
| Phenolphthalein | 77-09-8 | 600 | Salbutamol | 18559-94-9 | 37.5 |
| Phentermine | 122-09-8 | 1500 | Salicylamide | 65-45-2 | 600 |
| Phentolamine | 50-60-2 | 1500 | Salicylic acid | 69-72-7 | 900 |
| Phenylbutazone | 50-33-9 | 750 | Santonin | 481-06-1 | 450 |
| Phenylephrine | 59-42-7 | 2850 | Scopolamine | 6533-68-2 | 150 |
| Phenylpropanolamine | 14838-15-4 | 60 | Secobarbital | 76-73-3 | 900 |
| Pioglitazone | 111025-46-8 | 1200 | Sibutramine | 106650-56-0 | 1200 |
| Piperiacetildenafil | 147676-50-4 | 3000 | Sildenafil | 139755-83-2 | 1200 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 8 of 9



沅泰藥業有限公司

臺中市西區民權路185號10樓之14

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm($\mu\text{g/g}$)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-------------------------|-------------|------|-------------------------|-------------|------|
| Simvastatin | 79902-63-9 | 600 | Tetracycline | 60-54-8 | 750 |
| Spironolactone | 52-01-7 | 300 | Tetramethylpyrazine | 1124-11-4 | 2400 |
| Stanozolol | 10418-03-8 | 2100 | Theobromine | 83-67-0 | 600 |
| Strychnine | 57-24-9 | 900 | Theophylline | 58-55-9 | 600 |
| Sulfadiazine | 68-35-9 | 600 | Thiodimethylsildenafil | 856190-47-1 | 450 |
| Sulfadimethoxine | 122-11-2 | 750 | Thiohomosildenafil | 479073-80-8 | 450 |
| Sulfamerazine | 127-79-7 | 450 | Thioridazine | 50-52-2 | 300 |
| Sulfamethazine | 57-68-1 | 600 | Thiosildenafil | 479073-79-5 | 450 |
| Sulfamethizole | 144-82-1 | 600 | Tiletamine | 14176-49-9 | 300 |
| Sulfamethoxazole | 723-46-6 | 600 | Timolol Maleate | 26921-17-5 | 150 |
| Sulfamethoxypyridazine | 80-35-3 | 450 | Tinidazole | 19387-91-8 | 900 |
| Sulfamonomethoxine | 1220-83-3 | 4650 | Tolbutamide | 64-77-7 | 375 |
| Sulfanilamide | 63-74-1 | 375 | Topiramate | 97240-79-4 | 450 |
| Sulfapyridine | 144-83-2 | 2400 | Trazodone hydrochloride | 19794-93-5 | 3000 |
| Sulfaquinoxaline | 59-40-5 | 4740 | Triamcinolone | 124-94-7 | 900 |
| Sulfathiazole | 72-14-0 | 600 | Triamcinolone acetonide | 76-25-5 | 4800 |
| Sulfinpyrazone | 57-96-5 | 750 | Triazolam | 28911-01-5 | 150 |
| Sulfisomidine | 515-64-0 | 3000 | Trimethoprim | 738-70-5 | 1500 |
| Sulfisoxazole | 127-69-5 | 450 | Tripolidine | 486-12-4 | 60 |
| Sulindac | 38194-50-2 | 750 | Usnic acid | 125-46-2 | 3600 |
| Sulpiride | 15676-16-1 | 1140 | Vardenafil | 224785-90-4 | 1800 |
| Synephrine | 94-07-5 | 450 | Desulfovardenafil | 224789-21-3 | 1800 |
| Tadalafil | 171596-29-5 | 600 | Verapamil | 152-11-4 | 60 |
| Terbinafine | 91161-71-6 | 300 | Xanthinol Niacinate | 437-74-1 | 1050 |
| Terfenadine | 50679-08-8 | 450 | Yohimbine | 146-48-5 | 1500 |
| Testosterone | 58-22-0 | 600 | Zolazepam HCl | 31352-82-6 | 60 |
| Testosterone propionate | 57-85-2 | 3000 | Zolpidem | 82626-48-0 | 300 |
| Tetracaine | 94-24-6 | 600 | -- | -- | -- |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

報告編號： PUF26100472

日期： 2026年01月30日

頁數： 9 of 9



沅泰藥業有限公司


臺中市西區民權路185號10樓之14

樣品照片

PUF26100472



PUF26100472



PUF26100472



PUF26100472



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <https://www.sgs.com.tw/terms-of-service> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <https://www.sgs.com.tw/terms-of-service>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained herein reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： UB/2014/B0215 日期： 2014年11月20日 頁數： 1 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

以下測試之樣品係由申請廠商所提供及確認：

產品名稱： 舒沐康整合微細粒粉末+薑黃95%

申請廠商： 瑞法貿易有限公司

產品型號/批號： ---

生產或供應廠商： Viva pharmaceutical Inc.

樣品狀態： 完整包裝

製造日期： ---

有效期限： 2018年10月15日

收樣日期： 2014年11月06日

測試日期： 2014年11月07日

委託測試項目： 312項常見西藥成份分析

測試方法： 本測試參考衛生福利部食品藥物管理署建議方法-中藥及食品中摻加西藥之檢驗方法，以薄層析法(TLC)、液相層析離子阱質譜儀(LC/MS/MS)或氣相層析質譜儀(GC/MS)檢測。

測試結果： 此份樣品共檢測312項常見西藥成份(詳附錄)，均未檢出。

備註：1. 本報告不得分離，分離使用無效。

2. 檢測結果若大於方法偵測極限則匯整上表中，本次檢測項目及方法偵測極限分別詳列於附錄中。

3. 測試報告僅就委託測試者之委託事項提供測試結果，至若本產品之合法性，仍應由主管機關依法判斷。

Signed for and on behalf of
SGS Taiwan Ltd.

Yuan-Min Wen
Manager



測試報告

報告編號：

UB/2014/B0215

日期：2014年11月20日

頁數：2 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

附錄

測試項目及MDL匯整表： 單位:ppm(mg/kg)

| 測試項目 | 類別 | 方法偵測極限 | 測試項目 | 類別 | 方法偵測極限 |
|---------------------|---------|--------|-------------------------|-------|--------|
| Digitoxin | 心臟血管類用藥 | 100 | Meperidine | 局部麻醉類 | 10 |
| Dipyridamole | 心臟血管類用藥 | 10 | Chloramphenicol | 抗生素類 | 10 |
| Nylidrin | 心臟血管類用藥 | 10 | Econazole | 抗生素類 | 10 |
| Papaverine | 心臟血管類用藥 | 100 | Griseofulvin | 抗生素類 | 10 |
| Diltiazem | 心臟血管類用藥 | 10 | Lomefloxacin | 抗生素類 | 10 |
| Verapamil | 心臟血管類用藥 | 10 | Ketoconazole | 抗生素類 | 20 |
| Desacetyl diltiazem | 心臟血管類用藥 | 10 | Metronidazole | 抗生素類 | 10 |
| Prazosin | 心臟血管類用藥 | 10 | Nalidixic acid | 抗生素類 | 10 |
| Pentoxifylline | 心臟血管類用藥 | 10 | Nitrofurantoin | 抗生素類 | 100 |
| Benazepril | 心臟血管類用藥 | 50 | Minocycline | 抗生素類 | 20 |
| Bisoprolol Fumarate | 心臟血管類用藥 | 10 | Quinine | 抗生素類 | 10 |
| Carvedilol | 心臟血管類用藥 | 250 | Sulfaquinoxaline | 抗生素類 | 20 |
| Dihydroergotamine | 心臟血管類用藥 | 250 | Sulfamonomethoxine(SMM) | 抗生素類 | 20 |
| Doxazosin | 心臟血管類用藥 | 250 | Sulfadiazine | 抗生素類 | 20 |
| Aminophylline | 支氣管擴張劑 | 100 | Sulfadimethoxine | 抗生素類 | 10 |
| Theophylline | 支氣管擴張劑 | 100 | Sulfamerazine | 抗生素類 | 10 |
| Clenbuterol | 支氣管擴張劑 | 10 | Sulfamethazine | 抗生素類 | 10 |
| Dyphylline | 支氣管擴張劑 | 100 | Sulfamethizole | 抗生素類 | 100 |
| Fenoterol | 支氣管擴張劑 | 250 | Sulfamethoxazole | 抗生素類 | 10 |
| Salbutamol | 支氣管擴張劑 | 20 | Sulfamethoxypyridazine | 抗生素類 | 10 |
| Carisoprodol | 肌肉鬆弛劑 | 10 | Sulfanilamide | 抗生素類 | 100 |
| Chlormezanone | 肌肉鬆弛劑 | 100 | Sulfathiazole | 抗生素類 | 10 |
| Chlorzoxazone | 肌肉鬆弛劑 | 10 | Sulfisoxazole | 抗生素類 | 100 |
| Orphenadrine | 肌肉鬆弛劑 | 10 | Terbinafine | 抗生素類 | 10 |
| Zolazepam HCl | 肌肉鬆弛劑 | 10 | Tinidazole | 抗生素類 | 10 |
| Benzocaine | 局部麻醉類 | 50 | Tetracycline | 抗生素類 | 20 |
| Dibucaine | 局部麻醉類 | 10 | Trimethoprim | 抗生素類 | 10 |
| Diclofenac | 局部麻醉類 | 30 | Benzathine-penicillin | 抗生素類 | 250 |
| Lidocaine | 局部麻醉類 | 10 | Clindamycin phosphate | 抗生素類 | 20 |
| Procaine | 局部麻醉類 | 10 | Cloxacillin Sodium | 抗生素類 | 20 |
| Tetracaine | 局部麻醉類 | 10 | Chlortetracycline | 抗生素類 | 20 |
| Noscapine | 局部麻醉類 | 10 | Ciprofloxacin(CFA) | 抗生素類 | 10 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號：

UB/2014/B0215

日期：2014年11月20日

頁數：3 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

附錄

測試項目及MDL匯整表： 單位:ppm(mg/kg)

| 測試項目 | 類別 | 方法偵測極限 | 測試項目 | 類別 | 方法偵測極限 |
|------------------------|-------|--------|---------------------|----------|--------|
| Dimetridazole | 抗生素類 | 100 | Diethylpropion | 其他 | 10 |
| Enrofloxacin | 抗生素類 | 10 | Fenfluramine | 其他 | 10 |
| Lincomycin | 抗生素類 | 10 | Finasteride | 其他 | 10 |
| Difloxacin | 抗生素類 | 10 | Mazindol | 其他 | 10 |
| Ofloxacin | 抗生素類 | 10 | Phentermine | 其他 | 10 |
| Oxytetracycline (OTC) | 抗生素類 | 20 | Phentolamine | 其他 | 10 |
| Sulfisomidine | 抗生素類 | 10 | Phenylpropanolamine | 其他 | 500 |
| Santonin | 抗生素類 | 50 | Yohimbine | 其他 | 10 |
| Ampicillin | 抗生素類 | 20 | Nicotine | 其他 | 10 |
| Amoxicillin | 抗生素類 | 100 | Fluconazole | 其他 | 25 |
| Clindamycin HCl | 抗生素類 | 10 | Naltrexone | 其他 | 10 |
| Cephadrine | 抗生素類 | 50 | Simvastatin | 其他 | 10 |
| Ceftriaxone | 抗生素類 | 100 | Methaqualone | 其他 | 10 |
| Doxycycline | 抗生素類 | 20 | Metharbital | 其他 | 500 |
| Erythromycin | 抗生素類 | 10 | Clobenzorex | 其他 | 10 |
| Rifampin | 抗生素類 | 10 | Salicylic acid | 其他 | 250 |
| Cefotaxime | 抗生素類 | 10 | Methimazole | 治甲狀腺機能缺陷 | 100 |
| Nifuroxazide | 抗生素類 | 10 | Carbimazole | 治甲狀腺機能缺陷 | 200 |
| Nitrofurazone | 抗生素類 | 25 | Liothyronine | 治甲狀腺機能缺陷 | 10 |
| Cefoperazone dihydrate | 抗生素類 | 50 | Chlorothiazide | 泌尿系統用藥 | 10 |
| Cefamandole nafate | 抗生素類 | 10 | Flavoxate | 泌尿系統用藥 | 20 |
| Brompheniramine | 抗組織胺類 | 10 | Furosemide | 泌尿系統用藥 | 10 |
| Carbinoxamine | 抗組織胺類 | 10 | Hydrochlorothiazide | 泌尿系統用藥 | 500 |
| Chlorpheniramine | 抗組織胺類 | 10 | Phenazopyridine | 泌尿系統用藥 | 10 |
| Diphenhydramine | 抗組織胺類 | 10 | Sulfipyrazone | 泌尿系統用藥 | 10 |
| Terfenadine | 抗組織胺類 | 10 | Oxybutynin | 泌尿系統用藥 | 10 |
| Cyproheptadine | 抗組織胺類 | 10 | Norfloxacin | 泌尿系統用藥 | 10 |
| Cetirizine | 抗組織胺類 | 10 | Bezafibrate | 降血脂用藥 | 10 |
| Tripolidine | 抗組織胺類 | 10 | Fluvastatin | 降血脂用藥 | 10 |
| Ketotifen fumarate | 抗組織胺類 | 10 | Clofibrate | 降血脂用藥 | 50 |
| Astemizole | 抗組織胺類 | 10 | Etofibrate | 降血脂用藥 | 10 |
| Doxylamine | 抗組織胺類 | 10 | Fenofibrate | 降血脂用藥 | 10 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號：

UB/2014/B0215

日期：2014年11月20日

頁數：4 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

附錄

測試項目及MDL匯整表： 單位:ppm(mg/kg)

| 測試項目 | 類別 | 方法偵測極限 | 測試項目 | 類別 | 方法偵測極限 |
|---------------------------|--------|--------|-------------------------------|-------|--------|
| Gemfibrozil | 降血脂用藥 | 150 | Nandrolone | 荷爾蒙類 | 200 |
| Nicametate | 降血脂用藥 | 50 | Norethisterone acetate | 荷爾蒙類 | 10 |
| Xanthinol Niacinate | 降血脂用藥 | 10 | Oxymetholone | 荷爾蒙類 | 100 |
| Atorvastatin | 降血脂用藥 | 10 | Progesterone | 荷爾蒙類 | 10 |
| Atenolol | 降血壓用藥 | 10 | Stanozolol | 荷爾蒙類 | 10 |
| Hydralazine | 降血壓用藥 | 100 | Testosterone | 荷爾蒙類 | 100 |
| Minoxidil | 降血壓用藥 | 10 | Diethylstilbestrol | 荷爾蒙類 | 200 |
| Nifedipine | 降血壓用藥 | 10 | Estradiol | 荷爾蒙類 | 200 |
| Propranolol | 降血壓用藥 | 10 | Ethinylestradiol | 荷爾蒙類 | 500 |
| Reserpine | 降血壓用藥 | 10 | 7-Keto dehydroepiandrosterone | 減肥 | 10 |
| Timolol Maleate | 降血壓用藥 | 10 | N-Desmethyl sibutramine | 減肥 | 10 |
| Methyl DOPA-Sesquihydrate | 降血壓用藥 | 100 | N-Didesmethyl sibutramine | 減肥 | 10 |
| Indapamide | 降血壓用藥 | 50 | Orlistat | 減肥 | 10 |
| Amlodipine | 降壓、利尿類 | 10 | Rimonabant | 減肥 | 10 |
| Nitrazepam | 消化系統用藥 | 10 | Sibutramine | 減肥 | 10 |
| Apomorphine | 消化系統用藥 | 10 | Synephrine | 減肥 | 10 |
| Dimenhydrinate | 消化系統用藥 | 20 | Cetilistat | 減肥 | 10 |
| Methamphetamine | 神經興奮劑類 | 10 | Mephentermine | 減肥 | - |
| Morphine | 神經興奮劑類 | 100 | Atropine | 腸胃類用藥 | 10 |
| Pentazocine | 神經興奮劑類 | 10 | Bisacodyl | 腸胃類用藥 | 10 |
| Phenylephrine | 神經興奮劑類 | 100 | Butropium bromide | 腸胃類用藥 | 10 |
| Strychnine | 神經興奮劑類 | 10 | Camlyofine | 腸胃類用藥 | 10 |
| Theobromine | 神經興奮劑類 | 50 | Cimetidine | 腸胃類用藥 | 10 |
| Caffeine | 神經興奮劑類 | 10 | Dicyclomine | 腸胃類用藥 | 10 |
| Estrilol | 荷爾蒙類 | 100 | Glycopyrronium | 腸胃類用藥 | 10 |
| Estrone | 荷爾蒙類 | 50 | Homatropine | 腸胃類用藥 | 10 |
| Ethisterone | 荷爾蒙類 | 10 | Metoclopramide | 腸胃類用藥 | 250 |
| Ethylestrenol | 荷爾蒙類 | 100 | Oxethazaine | 腸胃類用藥 | 10 |
| Fluoxymesterone | 荷爾蒙類 | 10 | Oxyphencylimine | 腸胃類用藥 | 10 |
| Methandriol | 荷爾蒙類 | 100 | Phenolphthalein | 腸胃類用藥 | 10 |
| Methandrostenolone | 荷爾蒙類 | 10 | Pirenzepine | 腸胃類用藥 | 10 |
| Methyltestosterone | 荷爾蒙類 | 10 | Propantheline | 腸胃類用藥 | 10 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號：

UB/2014/B0215

日期：2014年11月20日

頁數：5 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

附錄

測試項目及MDL匯整表： 單位:ppm(mg/kg)

| 測試項目 | 類別 | 方法偵測極限 | 測試項目 | 類別 | 方法偵測極限 |
|--------------------------------|-------|--------|------------------|-------|--------|
| Ranitidine | 腸胃類用藥 | 10 | Acetylvardenafil | 補腎滋養 | 10 |
| Scopolamine N-butyl bromide | 腸胃類用藥 | 10 | Acetaminophen | 解熱止痛劑 | 100 |
| Vardenafil analogue(分子量312.37) | 補腎滋養 | 10 | Aminopyrine | 解熱止痛劑 | 10 |
| Acetil acid | 補腎滋養 | 10 | Benzbromarone | 解熱止痛劑 | 20 |
| Acetildenafil | 補腎滋養 | 10 | Bucetin | 解熱止痛劑 | 10 |
| Aminotadalafil | 補腎滋養 | 10 | Colchicine | 解熱止痛劑 | 10 |
| Carbodenafil | 補腎滋養 | 10 | Ethoxybenzamide | 解熱止痛劑 | 10 |
| Dimethylsildenafil | 補腎滋養 | 10 | Flurbiprofen | 解熱止痛劑 | 500 |
| Gendenafil | 補腎滋養 | 10 | Ibuprofen | 解熱止痛劑 | 500 |
| Homosildenafil | 補腎滋養 | 10 | Indomethacin | 解熱止痛劑 | 10 |
| Hydroxyacetildenafil | 補腎滋養 | 10 | Ketoprofen | 解熱止痛劑 | 20 |
| Hydroxyhomosildenafil | 補腎滋養 | 10 | Mefenamic acid | 解熱止痛劑 | 50 |
| Hydroxythiohomosildenafil | 補腎滋養 | 10 | Naproxen | 解熱止痛劑 | 50 |
| Vardenafil analogue(分子量437.54) | 補腎滋養 | 10 | Oxyphenbutazone | 解熱止痛劑 | 10 |
| Pseudovardenafil | 補腎滋養 | 10 | Phenylbutazone | 解熱止痛劑 | 10 |
| Sildenafil | 補腎滋養 | 10 | Piroxicam | 解熱止痛劑 | 10 |
| Tadalafil | 補腎滋養 | 10 | Probenecid | 解熱止痛劑 | 10 |
| Thiodimethylsildenafil | 補腎滋養 | 10 | Salicylamide | 解熱止痛劑 | 100 |
| Thiohomosildenafil | 補腎滋養 | 10 | Sulindac | 解熱止痛劑 | 10 |
| Thiosildenafil | 補腎滋養 | 10 | Acetophenetidin | 解熱止痛劑 | 10 |
| Vardenafil | 補腎滋養 | 10 | Benzydamine | 解熱止痛劑 | 10 |
| Noracetildenafil | 補腎滋養 | 10 | Bufexamac | 解熱止痛劑 | 100 |
| Nortadalafil | 補腎滋養 | 10 | Fenbufen | 解熱止痛劑 | 200 |
| Chloropretadalafil | 補腎滋養 | 10 | Flufenamic acid | 解熱止痛劑 | 10 |
| Imidazosagatriazinone | 補腎滋養 | 10 | Aspirin | 解熱止痛劑 | 100 |
| Dithio-desmethyl-carbodenafil | 補腎滋養 | 10 | Allopurinol | 解熱止痛劑 | 200 |
| Desmethyl sildenafil | 補腎滋養 | 10 | Amitriptyline | 精神用藥 | 10 |
| Desmethyl acetildenafil | 補腎滋養 | 10 | Amphetamine | 精神用藥 | 200 |
| Hydroxyvardenafil | 補腎滋養 | 10 | Benzhexol | 精神用藥 | 10 |
| N-Desethyl vardenafil | 補腎滋養 | 10 | Bromisoval | 精神用藥 | 200 |
| Norneosildenafil | 補腎滋養 | 10 | Chlordiazepoxide | 精神用藥 | 10 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號：

UB/2014/B0215

日期：2014年11月20日

頁數：6 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

附錄

測試項目及MDL匯整表： 單位:ppm(mg/kg)

| 測試項目 | 類別 | 方法偵測極限 | 測試項目 | 類別 | 方法偵測極限 |
|-------------------|-------|--------|--------------------------------------|-------|--------|
| Chlorpromazine | 精神用藥 | 10 | Chlorpropamide | 糖尿病用藥 | 10 |
| Cinnarizine | 精神用藥 | 10 | Glibenclamide(Glyburide) | 糖尿病用藥 | 10 |
| Cocaine | 精神用藥 | 10 | Glipizide | 糖尿病用藥 | 20 |
| Diazepam | 精神用藥 | 10 | Metformin | 糖尿病用藥 | 10 |
| Diphenylhydantoin | 精神用藥 | 100 | Phenformin | 糖尿病用藥 | 10 |
| Fluoxetine | 精神用藥 | 10 | Pioglitazone | 糖尿病用藥 | 10 |
| Lorazepam | 精神用藥 | 25 | Tolbutamide | 糖尿病用藥 | 10 |
| Melatonin | 精神用藥 | 20 | Rosiglitazone | 糖尿病用藥 | 10 |
| Mephenesin | 精神用藥 | 100 | Bromhexine | 鎮咳祛痰劑 | 10 |
| Meprobamate | 精神用藥 | 100 | Carbetapentane | 鎮咳祛痰劑 | 10 |
| Phenobarbital | 精神用藥 | 1000 | Dextromethorphan | 鎮咳祛痰劑 | 10 |
| Quetiapine | 精神用藥 | 10 | Guaiacol Glyceryl Ether(Guaifenesin) | 鎮咳祛痰劑 | 10 |
| Primidone | 精神用藥 | 20 | Phenacetin | 鎮咳祛痰劑 | 10 |
| Secobarbital | 精神用藥 | 500 | Ambroxol | 鎮咳祛痰劑 | 10 |
| Thioridazine | 精神用藥 | 10 | Cloperastine | 鎮咳祛痰劑 | 10 |
| Zolpidem | 精神用藥 | 10 | Eprazinone | 鎮咳祛痰劑 | 250 |
| Haloperidol | 精神用藥 | 10 | Betamethasone | 類固醇類 | 10 |
| Sulpiride | 精神用藥 | 10 | Cortisone | 類固醇類 | 10 |
| Cephalexin | 精神用藥 | 10 | Dexamethasone | 類固醇類 | 50 |
| Cefazolin | 精神用藥 | 20 | Hydrocortisone | 類固醇類 | 10 |
| Carbamazepine | 精神用藥 | 10 | Methylprednisolone | 類固醇類 | 20 |
| Triazolam | 精神用藥 | 10 | Prednisolone | 類固醇類 | 20 |
| Imipramine | 精神用藥 | 10 | Prednisone | 類固醇類 | 10 |
| Estazolam | 精神用藥 | 10 | Triamcinolone | 類固醇類 | 50 |
| Clonazepam | 精神用藥 | 100 | Betamethasone 21 Acetate | 類固醇類 | 10 |
| Midazolam | 精神用藥 | 10 | Betamethasone Benzoate | 類固醇類 | 10 |
| Buspiron | 精神用藥 | 10 | Betamethasone Dipropionate | 類固醇類 | 10 |
| Barbital | 精神用藥 | 200 | Betamethasone Valerate | 類固醇類 | 10 |
| Acetohexamide | 糖尿病用藥 | 200 | Dexamethasone phosphate | 類固醇類 | 100 |

-END-

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號：

UB/2014/B0215

日期：2014年11月20日

頁數：7 of 7



瑞法貿易有限公司

台中市南屯區大墩一街57巷7號1樓

樣品照片

UB/2014/B0215



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.